PL4023249T3 - Szczepionki z kwasem nukleinowym - Google Patents

Szczepionki z kwasem nukleinowym

Info

Publication number
PL4023249T3
PL4023249T3 PL21195046.4T PL21195046T PL4023249T3 PL 4023249 T3 PL4023249 T3 PL 4023249T3 PL 21195046 T PL21195046 T PL 21195046T PL 4023249 T3 PL4023249 T3 PL 4023249T3
Authority
PL
Poland
Prior art keywords
nucleic acid
acid vaccines
vaccines
nucleic
acid
Prior art date
Application number
PL21195046.4T
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Axel Bouchon
Eric Yi-Chen Huang
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4023249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of PL4023249T3 publication Critical patent/PL4023249T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21195046.4T 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym PL4023249T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983250P 2014-04-23 2014-04-23
US201462088994P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
PL4023249T3 true PL4023249T3 (pl) 2025-03-10

Family

ID=54333225

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21195046.4T PL4023249T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL21191353.8T PL3981437T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL15783606T PL3134131T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL21191353.8T PL3981437T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL15783606T PL3134131T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym

Country Status (23)

Country Link
US (10) US10022435B2 (pl)
EP (4) EP4023249B1 (pl)
JP (3) JP6881813B2 (pl)
CN (1) CN106659803A (pl)
AU (3) AU2015249553B2 (pl)
BR (1) BR112016024644A2 (pl)
CA (2) CA2946751A1 (pl)
CY (1) CY1125084T1 (pl)
DK (3) DK3134131T3 (pl)
ES (3) ES2909180T3 (pl)
FI (2) FI3981437T3 (pl)
HR (3) HRP20241732T1 (pl)
HU (3) HUE069802T2 (pl)
LT (3) LT3981437T (pl)
MA (2) MA58292B1 (pl)
PL (3) PL4023249T3 (pl)
PT (3) PT3134131T (pl)
RS (3) RS63050B1 (pl)
RU (2) RU2746406C2 (pl)
SG (2) SG10201912038TA (pl)
SI (3) SI3981437T1 (pl)
SM (3) SMT202500053T1 (pl)
WO (1) WO2015164674A1 (pl)

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112014030677A2 (pt) 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
EP2970955B1 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. Methods for purification of messenger rna
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
WO2014153052A2 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
HUE071526T2 (hu) 2013-03-15 2025-09-28 Translate Bio Inc Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6474391B2 (ja) * 2013-06-11 2019-02-27 ビオカルティ ナームローゼ フェノーツハップＢｉｏｃａｒｔｉｓ ＮＶ 長期貯蔵のための生体分子乾燥方法
HUE056760T2 (hu) 2013-07-11 2022-03-28 Modernatx Inc A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) * 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
BR112016008832A2 (pt) 2013-10-22 2017-10-03 Shire Human Genetic Therapies Distribuição de mrna no snc e suas utilizações
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
IL298516B2 (en) 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
WO2016011222A2 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
SI3313829T1 (sl) 2015-06-29 2024-09-30 Acuitas Therapeutics Inc. Lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US20190008887A1 (en) * 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN108473969B9 (zh) 2015-10-14 2024-08-23 川斯勒佰尔公司 用于增强生产的rna相关酶的修饰
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
EA201890999A1 (ru) * 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против вируса простого герпеса
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
CN109310751A (zh) 2015-10-22 2019-02-05 摩登纳特斯有限公司 广谱流感病毒疫苗
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US10851136B2 (en) * 2015-11-19 2020-12-01 Creation Plus Biotechnology Co. Ltd Recombinant lactic acid bacteria and the use thereof in oral universal influenza vaccine
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3825400B1 (en) 2016-04-08 2024-12-25 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
CN116077439A (zh) 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
DK3458083T5 (da) 2016-05-18 2024-10-21 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
EP3896164A1 (en) * 2016-05-18 2021-10-20 ModernaTX, Inc. Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
LT3458474T (lt) * 2016-05-18 2022-10-10 Modernatx, Inc. Imunitetą moduliuojančius polipeptidus koduojančių mrnr deriniai ir jų naudojimas
CA3027312A1 (en) 2016-06-13 2017-12-21 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
WO2018009838A1 (en) 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
US11555177B2 (en) * 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3493834A1 (en) * 2016-08-07 2019-06-12 Novartis AG Mrna-mediated immunization methods
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
CA3039089A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
EP3532097A1 (en) * 2016-10-27 2019-09-04 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CN110381994B (zh) 2017-01-11 2024-05-10 宾夕法尼亚大学理事会 用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
WO2018170270A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595676A4 (en) * 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN107300583A (zh) * 2017-04-18 2017-10-27 武汉博沃生物科技有限公司 疫苗中蔗糖含量的检测方法及其应用
EP3641810A4 (en) * 2017-04-26 2021-08-18 Modernatx, Inc. VACCINES AGAINST HERPES SIMPLEX VIRUS
JP7464954B2 (ja) 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
WO2018222983A1 (en) 2017-06-02 2018-12-06 Shackelton Laura Phenotypically wild-type and genetically attenuated viruses
CA3065111A1 (en) * 2017-06-02 2018-12-06 Laura SHACKELTON Genetically attenuated nucleic acid vaccine
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US12065396B2 (en) 2017-08-17 2024-08-20 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20200254086A1 (en) * 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP4397757A3 (en) 2017-08-18 2024-10-23 ModernaTX, Inc. Rna polymerase variants
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
EA202090873A1 (ru) * 2017-09-29 2020-08-17 Интеллиа Терапьютикс, Инк. Полинуклеотиды, композиции и способы редактирования генома
WO2019070730A1 (en) 2017-10-02 2019-04-11 Duke University MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
IL321714A (en) * 2017-10-19 2025-08-01 CureVac SE Novel artificial nucleic acid molecules
GB201718660D0 (en) * 2017-11-10 2017-12-27 Ucl Business Plc Improved liposome for mRNA delivery to cells
WO2019103993A1 (en) * 2017-11-21 2019-05-31 Modernatx, Inc. Epstein-barr virus vaccines
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
US10785574B2 (en) 2017-12-14 2020-09-22 Flodesign Sonics, Inc. Acoustic transducer driver and controller
BR112020011670A2 (pt) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. composições compreendendo polirribonucleotídeos circulares e seus usos
EP3727428A1 (en) 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
CN111818940A (zh) * 2018-01-05 2020-10-23 安德烈亚斯·罗尔夫-乔纳斯·尼尔森 用作疫苗的内源性肿瘤衍生的环状rna及其蛋白质
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
MA54676A (fr) * 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2019158653A1 (en) * 2018-02-15 2019-08-22 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
TWI682779B (zh) * 2018-04-03 2020-01-21 林淑卿 豬疾病疫苗用佐劑及其製備方法
US11679159B2 (en) * 2018-04-29 2023-06-20 Precision NanoSystems ULC Compositions for transfecting resistant cell types
MA52625A (fr) * 2018-05-16 2021-03-24 Translate Bio Inc Lipides cationiques de ribose
CN108795935B (zh) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
AU2019299217B2 (en) 2018-07-03 2025-04-03 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate
CN112930396B (zh) 2018-08-24 2024-05-24 川斯勒佰尔公司 用于纯化信使rna的方法
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
AU2019336679B2 (en) 2018-09-04 2025-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
JP7640452B2 (ja) * 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
IL281615B1 (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CA3110914A1 (en) 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
CA3115232A1 (en) * 2018-10-01 2020-04-09 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CN113166783B (zh) * 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20200157157A1 (en) 2018-11-21 2020-05-21 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
US12042527B2 (en) 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020205717B2 (en) 2019-01-11 2025-09-11 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
KR20210142678A (ko) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
CN109880835B (zh) * 2019-03-28 2022-03-25 扬州大学 重组h9n2禽流感病毒株、其制备方法、禽流感疫苗及其应用
US11197820B2 (en) * 2019-04-30 2021-12-14 The Medical College Of Wisconsin, Inc. Trans-tympanic membrane delivery platform and uses thereof
CN115867291A (zh) 2019-05-22 2023-03-28 麻省理工学院 环状rna组合物和方法
MA56535A (fr) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Co Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
EP4027982A1 (en) * 2019-09-11 2022-07-20 ModernaTX, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
CN110897032B (zh) * 2019-11-19 2025-10-14 华南理工大学 一种发酵饲料蛋白及其制备方法与应用
MX2022006854A (es) 2019-12-04 2022-11-30 Orna Therapeutics Inc Composiciones y metodos de arn circular.
US20230008380A1 (en) 2019-12-09 2023-01-12 University Of Georgia Research Foundation, Inc. M. tuberculosis ag85 proteins and methods of use
WO2021141944A1 (en) * 2020-01-07 2021-07-15 Translate Bio Ma, Inc. Formulations for delivery of oligonucleotides to lung cells
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP4100052A2 (en) * 2020-02-07 2022-12-14 ModernaTX, Inc. Sars-cov-2 mrna domain vaccines
WO2021160346A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CA3170239A1 (en) * 2020-02-14 2021-08-19 Etherna Immunotherapies Nv Intranasal mrna vaccines
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
AU2021271300A1 (en) 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. RNA replicon encoding a stabilized corona virus spike protein
CN111647557A (zh) * 2020-05-18 2020-09-11 中国人民解放军第四军医大学 一种表面偶联s蛋白的外泌体及其制备方法和应用
CN113679701B (zh) * 2020-05-18 2024-04-30 中国科学院上海药物研究所 邻苯三酚及其衍生物作为共价配体反应弹头的用途
WO2021236855A1 (en) * 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
JP2023530229A (ja) * 2020-05-29 2023-07-14 キュアバック エスイー 核酸ベースの混合ワクチン
JP7672657B2 (ja) * 2020-06-11 2025-05-08 第一三共株式会社 核酸脂質粒子ワクチン
CN111714621B (zh) * 2020-06-29 2021-04-27 中国科学院昆明动物研究所 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022015513A2 (en) 2020-07-13 2022-01-20 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to assess rna stability
CA3189338A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CA3187345A1 (en) * 2020-07-31 2022-02-17 Romain MICOL Compositions and methods for improved vaccination
WO2022031376A1 (en) * 2020-08-03 2022-02-10 Avalon GloboCare Corp. Emulsomes comprising s-layer fusion proteins and methods of use thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022047427A2 (en) 2020-08-31 2022-03-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
AU2021360494A1 (en) 2020-10-14 2023-05-18 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
WO2022091119A1 (en) * 2020-10-26 2022-05-05 Gunjan Kumar A pharmaceutical kit comprising copper sulfate and ascorbic acid
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
CN112358545B (zh) * 2020-11-10 2022-03-01 中国农业大学 鸽毛滴虫与白色念珠菌二联卵黄抗体粉的制备方法及应用
US20220175690A1 (en) * 2020-11-17 2022-06-09 Phosphorex, Inc. Novel drug delivery composition and process for blood-brain barrier crossing
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
GB202019916D0 (en) * 2020-12-16 2021-01-27 Imperial College Innovations Ltd RNA vaccine
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US12263217B2 (en) 2020-12-23 2025-04-01 Daykin Molecular Systems, LLC Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US20240066119A1 (en) * 2021-01-13 2024-02-29 University Of Maryland, College Park Methods and platforms for eliciting an immune response in the treatment of cancer and compositions and vaccines relating thereto
AU2022208057A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN117177736A (zh) * 2021-03-08 2023-12-05 德克萨斯大学系统董事会 核酸脂质纳米颗粒的干燥粉末制剂
US11859021B2 (en) 2021-03-19 2024-01-02 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
US11260113B1 (en) 2021-03-26 2022-03-01 King Abdulaziz University NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US20240336672A1 (en) 2021-04-26 2024-10-10 Institut Pasteur Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
JPWO2022244825A1 (pl) 2021-05-19 2022-11-24
EP4342491A4 (en) 2021-05-19 2025-08-20 Nat Inst Biomedical Innovation Health & Nutrition HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE
CN113476598A (zh) * 2021-07-20 2021-10-08 武汉圣润生物科技有限公司 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用
US12251471B2 (en) 2021-07-26 2025-03-18 Oregon State University Inhalable therapeutics
WO2023008881A1 (ko) * 2021-07-29 2023-02-02 주식회사 에스엠엘바이오팜 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물
EP4387597A1 (en) * 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
EP4387596A1 (en) * 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
AU2022361756A1 (en) * 2021-10-06 2024-05-02 Seqirus Inc. Lipid nanoparticle comprising a nucleic acid-binding protein
MX2024004177A (es) * 2021-10-08 2024-04-23 Pfizer Composiciones inmunogenicas de lnp y metodos de los mismos.
US20250281583A1 (en) 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
KR20240090727A (ko) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. Mrna 백신 조성물
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4436588A1 (en) 2021-11-23 2024-10-02 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
CN115813848B (zh) * 2021-12-10 2023-08-08 上海臻上医药科技有限公司 微针注射mRNA编码双特异性抗体药物的试剂、方法和应用
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4452282A4 (en) * 2021-12-22 2025-10-29 Terence Francis Mullins SYSTEM AND METHOD FOR ANTIBODY ACTIVATORS IN AN AQUEOUS IODINE SOLUTION
EP4460326A2 (en) * 2022-01-07 2024-11-13 HDT Bio Corp. Compositions and methods for multivalent immune responses
CN114437237B (zh) * 2022-01-12 2023-10-24 黑龙江八一农垦大学 金黄色葡萄球菌trap靶向重组蛋白抗原及其用途
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN115304756B (zh) * 2022-01-30 2023-05-09 上海科技大学 一种五元脂质纳米颗粒及其制备方法和应用
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN119365208A (zh) 2022-04-13 2025-01-24 巴塞罗那自治大学 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
CN116942610A (zh) * 2022-04-29 2023-10-27 北京祥瑞生物制品股份有限公司 一种核酸药物递送系统及其制备方法
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
CN114591386B (zh) * 2022-05-10 2022-09-09 深圳厚存纳米药业有限公司 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
EP4531902A1 (en) 2022-05-25 2025-04-09 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
EP4296274A1 (en) 2022-06-23 2023-12-27 Universidade de Santiago de Compostela Peptides for intracellular delivery
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024020453A2 (en) * 2022-07-20 2024-01-25 Hdt Bio Corp. Immune system modulators and uses thereof
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
GB202216449D0 (en) 2022-11-04 2022-12-21 Io Biotech Aps TGF-BETA1 vaccine
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024140767A1 (zh) 2022-12-29 2024-07-04 仁景(苏州)生物科技有限公司 用于预防或治疗hpv感染相关疾病的多核苷酸分子
EP4654952A1 (en) 2023-01-27 2025-12-03 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
EP4410316A1 (en) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticles for delivery of nucleic acid cargos
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
AU2024271830A1 (en) * 2023-05-12 2025-11-27 Seqirus Inc. Vaccine adjuvants
WO2024238881A1 (en) * 2023-05-17 2024-11-21 The Regents Of The University Of Michigan Compositions and methods for preventing and treating candida auris infection
WO2024254518A2 (en) * 2023-06-07 2024-12-12 Nvelop Therapeutics, Inc. Compositions of lipid delivery particles and method of use thereof
WO2025006263A2 (en) * 2023-06-27 2025-01-02 Cz Biohub Sf, Llc Design of universal influenza vaccine candidates via antigen reorientation
WO2025007148A1 (en) * 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054360A1 (en) * 2023-09-05 2025-03-13 The Regents Of The University Of California Injectable hydrogel for sustained co-delivery of an antigen and an adjuvant, and uses thereof
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025219454A1 (en) 2024-04-18 2025-10-23 Poltreg S.A. Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes
WO2025231407A1 (en) * 2024-05-03 2025-11-06 Nutech Ventures Lipid nanoparticles and methods of making and using
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
CN119424376B (zh) * 2025-01-13 2025-07-25 北京大学 一种可超声靶向的脂质纳米颗粒及其应用

Family Cites Families (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204401A1 (en) 1985-04-09 1986-12-10 Biogen, Inc. Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
EP0802980A1 (en) 1994-06-02 1997-10-29 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1997048370A2 (en) 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5989911A (en) 1997-05-09 1999-11-23 University Of Massachusetts Site-specific synthesis of pseudouridine in RNA
JP2002508299A (ja) 1997-09-19 2002-03-19 セクイター， インク． センスｍＲＮＡ治療
WO1999018221A1 (en) 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US20090017533A1 (en) 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
WO2000050586A2 (en) 1999-02-22 2000-08-31 European Molecular Biology Laboratory In vitro translation system
AU778809B2 (en) 1999-03-29 2004-12-23 Statens Serum Institut Method for producing a nucleotide sequence construct with optimised codons for an HIV genetic vaccine based on primary, early HIV isolate and synthetic envelope BX08 constructs
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
WO2001023002A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
CN1981873A (zh) 2000-06-09 2007-06-20 莱古伦公司 制备微胶粒的方法和所述微胶粒的用途
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
ES2295351T3 (es) 2001-04-21 2008-04-16 Curevac Gmbh Dispositivo para la inyeccion de rnam.
PT1857122E (pt) 2001-06-05 2011-03-07 Curevac Gmbh Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE60336736D1 (de) 2002-07-16 2011-05-26 VGX Pharmaceuticals LLC Codon-optimierte synthetische plasmide
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
WO2005027963A2 (en) 2003-09-15 2005-03-31 The United States Of America As Represented By Thesecretary Of Health And Human Services, Nih METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV
US20050065114A1 (en) 2003-09-23 2005-03-24 Jean-Claude Yvin Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CA2569645C (en) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20090088374A1 (en) 2005-01-07 2009-04-02 Judithann Lee Novel use
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
US20120021042A1 (en) 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
AU2006338210A1 (en) 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
DK1976871T3 (da) 2006-01-13 2011-12-12 Univ Pennsylvania Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
EP2295045A1 (en) 2006-07-07 2011-03-16 Aarhus Universitet Nanoparticles for nucleic acid delivery
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
KR101559184B1 (ko) * 2006-08-09 2015-10-13 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
WO2008143640A1 (en) * 2006-11-07 2008-11-27 Government Of The United Nations Of America, As Represented By The Secretariat, Department Of Healthand Human Services Influenza virus nucleic acid microarray and method of use
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
US8268586B2 (en) 2006-12-21 2012-09-18 Novozymes, Inc. Modified messenger RNA stabilizing sequences for expressing genes in bacterial cells
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
ATE525392T1 (de) 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2008109712A2 (en) 2007-03-05 2008-09-12 Washington University Nanoparticle delivery systems for membrane-integrating peptides
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
MX2009013046A (es) 2007-05-30 2010-02-17 Univ Northwestern Nanoparticulas con grupo funcional de acido nucleico para aplicaciones terapeuticas.
MX2009013008A (es) 2007-05-31 2010-06-09 Vacunas para la influenza.
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
US20110086904A1 (en) 2007-09-17 2011-04-14 The Trustees Of The University Of Pennsylvania GENERATION OF HYPERSTABLE mRNAs
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
US8470560B2 (en) 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009062348A1 (en) 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
US8081186B2 (en) 2007-11-16 2011-12-20 Microsoft Corporation Spatial exploration field of view preview mechanism
EP3346005A1 (en) 2008-01-31 2018-07-11 CureVac AG Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
US20120027813A1 (en) 2008-02-22 2012-02-02 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines for pediatric use
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
WO2009119722A1 (ja) * 2008-03-28 2009-10-01 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
CA2730737A1 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
WO2010009065A2 (en) 2008-07-15 2010-01-21 Novartis Ag Amphipathic peptide compositions
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PL2350043T3 (pl) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP2902013A1 (en) 2008-10-16 2015-08-05 Marina Biotech, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010054406A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
ES2614802T3 (es) 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
WO2010088537A2 (en) 2009-01-29 2010-08-05 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
WO2010098861A1 (en) 2009-02-24 2010-09-02 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
US8460696B2 (en) 2009-03-20 2013-06-11 Egen, Inc. Polyamine derivatives
EP2421563B1 (en) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Innate immune suppression enables repeated delivery of long rna molecules
NZ711583A (en) 2009-05-05 2017-03-31 Arbutus Biopharma Corp Lipid compositions
KR102066189B1 (ko) 2009-06-10 2020-01-14 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EA201270019A1 (ru) * 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
WO2010148085A1 (en) 2009-06-16 2010-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rna nanoparticles and methods of use
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
EP3165234B1 (de) 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
WO2011017548A1 (en) 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2011031298A1 (en) 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
JP5823405B2 (ja) 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
RS58405B1 (sr) 2009-12-01 2019-04-30 Translate Bio Inc Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima
KR101878502B1 (ko) 2009-12-07 2018-07-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제
NZ600725A (en) 2009-12-18 2015-08-28 Univ British Colombia Methods and compositions for delivery of nucleic acids
MX348474B (es) 2009-12-23 2017-06-14 Novartis Ag * Lipidos, composiciones de lipido, y metodos de uso de los mismos.
US20110184160A1 (en) 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
EP2558074B1 (en) * 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
EP2575895A2 (en) 2010-05-24 2013-04-10 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
CN106177940A (zh) 2010-05-26 2016-12-07 西莱克塔生物科技公司 含有佐剂的合成纳米载体的剂量选择
EP2575767B1 (en) 2010-06-04 2017-01-04 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
HRP20161352T1 (hr) 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
RU2625546C2 (ru) 2010-07-06 2017-07-14 Новартис Аг Катионные эмульсии "масло-в-воде"
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
US20120058153A1 (en) 2010-08-20 2012-03-08 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
WO2012027365A2 (en) 2010-08-23 2012-03-01 Selecta Biosciences, Inc. Targeted multi-epitope dosage forms for induction of an immune response to antigens
KR20130100278A (ko) 2010-08-31 2013-09-10 머크 샤프 앤드 돔 코포레이션 올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
DK4226941T3 (da) 2010-08-31 2024-12-02 Glaxosmithkline Biologicals Sa Pegylerede liposomer til levering af immunogen-kodende rna
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
EP4043040B1 (en) 2010-08-31 2023-01-11 GlaxoSmithKline Biologicals SA Small liposomes for delivery of immunogen-encoding rna
WO2012040184A2 (en) 2010-09-20 2012-03-29 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CA2821992A1 (en) * 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US9029590B2 (en) 2010-10-21 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
MX346784B (es) 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
MX344972B (es) 2010-11-16 2017-01-12 Selecta Biosciences Inc Oligonucleotidos inmunoestimulantes.
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012092569A2 (en) 2010-12-31 2012-07-05 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
CA2834349A1 (en) 2011-04-26 2012-11-01 Molecular Express, Inc. Liposomal formulations
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US20140206752A1 (en) 2011-05-17 2014-07-24 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
DK2714017T3 (en) 2011-06-02 2018-09-03 Univ California MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
ES2987057T3 (es) 2011-06-08 2024-11-13 Translate Bio Inc Lípidos escindibles
US8916696B2 (en) 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
AU2012280901B2 (en) 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
US9008142B2 (en) 2011-07-22 2015-04-14 Insight Photonic Solutions, Inc. System and method for optimization of coherence length of tunable laser sources
US9018089B2 (en) 2011-08-30 2015-04-28 International Business Machines Corporation Multiple step anneal method and semiconductor formed by multiple step anneal
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
JP2014525435A (ja) 2011-09-02 2014-09-29 ノバルティス アーゲー Ｈｓｆ１関連疾患を処置するための有機組成物
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2953393T3 (es) * 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
CA2872033A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
CA2852917C (en) 2011-10-18 2020-07-07 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
CN107441484A (zh) 2011-11-03 2017-12-08 森提耐斯特治疗公司 针对人肠道病毒的抗原及疫苗
CN103906504B (zh) 2011-11-04 2017-11-17 日东电工株式会社 制备用于药物递送的脂质纳米颗粒的方法
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
US9504741B2 (en) * 2011-11-23 2016-11-29 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US9839616B2 (en) 2011-12-12 2017-12-12 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
CA2858694A1 (en) 2011-12-12 2013-06-20 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipids
EP2791159A4 (en) * 2011-12-14 2015-10-14 Moderna Therapeutics Inc MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF
EP2791364A4 (en) 2011-12-14 2015-11-11 Moderna Therapeutics Inc PROCESS FOR RESPONSE TO A BIOLOGICAL THREAT
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
RU2014129863A (ru) 2011-12-21 2016-02-10 Модерна Терапьютикс, Инк. Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013135359A1 (en) 2012-03-16 2013-09-19 Merck Patent Gmbh Targeting aminoacid lipids
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9717685B2 (en) 2012-03-26 2017-08-01 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
EP3865123A1 (en) 2012-03-29 2021-08-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
BR112014030677A2 (pt) * 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
PT3489220T (pt) 2012-06-08 2021-10-22 Nitto Denko Corp Lípidos para formulações de administração de agentes terapêuticos
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
WO2014028763A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
US20150202153A1 (en) 2012-10-04 2015-07-23 University Of The Witwatersrand, Johannesburg Liposomal drug delivery system
KR102315098B1 (ko) 2012-11-01 2021-10-21 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
TW201920677A (zh) 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP3628335B1 (en) 2012-12-07 2023-11-08 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery in the lungs
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
HK1214962A1 (zh) 2013-01-10 2016-08-12 Seqirus UK Limited 流感病毒免疫原性组合物及其应用
ES2649180T3 (es) 2013-02-22 2018-01-10 Curevac Ag Combinación de vacunación e inhibición de la ruta PD-1
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP6605446B2 (ja) 2013-03-15 2019-11-13 ザ ユニバーシティ オブ ブリティッシュ コロンビア 形質移入用の脂質ナノ粒子および関連方法
AU2014233424B2 (en) 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
HUE071526T2 (hu) 2013-03-15 2025-09-28 Translate Bio Inc Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel
WO2014140211A1 (en) 2013-03-15 2014-09-18 Novartis Ag Rna purification methods
KR20150127586A (ko) 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 핵산 분자 및 이로부터 제조된 백신
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US8980864B2 (en) * 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2803508T3 (es) 2013-03-28 2021-01-27 Medicago Inc Producción de partículas similares al virus de la gripe en plantas
TW201515650A (zh) 2013-05-06 2015-05-01 艾爾妮蘭製藥公司 遞送經脂質調配之核酸分子之劑量及方法
US9895443B2 (en) 2013-06-26 2018-02-20 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
HUE056760T2 (hu) 2013-07-11 2022-03-28 Modernatx Inc A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
CN105555757A (zh) 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
EP3677279A1 (en) 2013-07-25 2020-07-08 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
US10398769B2 (en) 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015058069A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
CN112656954A (zh) 2013-10-22 2021-04-16 夏尔人类遗传性治疗公司 用于递送信使rna的脂质制剂
EP2883872A1 (en) 2013-12-16 2015-06-17 Universite De Bordeaux I Five-membered cyclic biscarbonates bearing amide linkages, their preparation and their uses for the preparation of polyhydroxyurethanes
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
EP3129050A2 (en) 2014-04-01 2017-02-15 CureVac AG Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
SG10201912038TA (en) * 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
IL298516B2 (en) 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3169783A4 (en) 2014-07-17 2018-10-03 Modernatx, Inc. Terminal modifications of polynucleotides
EP3188760B1 (en) 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
JP6912384B2 (ja) 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
AU2016264027A1 (en) 2015-05-15 2017-08-31 Curevac Ag Prime-boost regimens involving administration of at least one mRNA construct
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US11364292B2 (en) * 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
CA2998810A1 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
HUE065704T2 (hu) 2015-09-21 2024-06-28 Trilink Biotechnologies Llc Készítmények és módszerek 5-sapkával ellátott RNS-ek szintetizálására
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
AU2016341311B2 (en) 2015-10-22 2023-11-16 Modernatx, Inc. Respiratory syncytial virus vaccine
CN109310751A (zh) 2015-10-22 2019-02-05 摩登纳特斯有限公司 广谱流感病毒疫苗
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EA201890999A1 (ru) 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против вируса простого герпеса
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
US20180318409A1 (en) 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
CA3007108A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US11377656B2 (en) 2016-03-10 2022-07-05 Novartis Ag Chemically modified messenger RNA's
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
MA45032A (fr) 2016-05-18 2019-03-27 Fundacion Para La Investig Medica Aplicada Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
EP3896164A1 (en) 2016-05-18 2021-10-20 ModernaTX, Inc. Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
SG11201810162PA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
MA45041A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
DK3458083T5 (da) 2016-05-18 2024-10-21 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3034681A1 (en) 2016-06-30 2018-01-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
EP3528827A4 (en) 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN110402145A (zh) 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
IL317855A (en) 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
EP3532613A4 (en) 2016-10-26 2020-05-06 ModernaTX, Inc. METHOD AND COMPOSITIONS FOR RNA MAPPING
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
SG11201906744VA (en) 2017-01-27 2019-08-27 Methodist Hospital Core/shell structure platform for immunotherapy
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
WO2018144778A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
EP3596041B1 (en) 2017-03-15 2022-11-02 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
EP3641810A4 (en) 2017-04-26 2021-08-18 Modernatx, Inc. VACCINES AGAINST HERPES SIMPLEX VIRUS
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2019018765A1 (en) 2017-07-21 2019-01-24 Modernatx, Inc. MODIFIED mRNA ENCODING PROPIONYL-COA-CARBOXYLASE AND USES THEREOF
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
EP4397757A3 (en) 2017-08-18 2024-10-23 ModernaTX, Inc. Rna polymerase variants
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019089818A1 (en) 2017-10-31 2019-05-09 Modernatx, Inc. Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
WO2019103993A1 (en) 2017-11-21 2019-05-31 Modernatx, Inc. Epstein-barr virus vaccines
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
KR20210038886A (ko) 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
EP3863645A4 (en) 2018-09-13 2022-11-16 ModernaTX, Inc. MODIFIED mRNA FOR THE TREATMENT OF FAMILY PROGRESSIVE INTRAHEPATIC CHOLESTASIS DISORDERS
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP7640452B2 (ja) 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MA54192A (fr) 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
WO2020160397A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
KR20220018960A (ko) 2019-03-19 2022-02-15 아크투루스 쎄라퓨틱스, 인크. 지질-캡슐화된 rna 나노입자 제조 방법
MA56060A (fr) 2019-05-31 2022-04-06 Modernatx Inc Dosage de lymphocytes t ayant subi une expansion
AU2020329226A1 (en) 2019-08-14 2022-02-24 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
CA3154082A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Human cytomegalovirus vaccine
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20220349006A1 (en) 2019-09-19 2022-11-03 Moderna TX, Inc. Cap guides and methods of use thereof for rna mapping
EP4088281A4 (en) 2020-01-10 2024-02-21 ModernaTX, Inc. VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
EP4096683A4 (en) 2020-01-30 2024-04-10 ModernaTX, Inc. IMMUNIZATION COMPOSITIONS FOR RESPIRATORY VIRUSES
KR20220133957A (ko) 2020-01-31 2022-10-05 모더나티엑스, 인크. 지질 나노입자의 제조 방법
EP4100052A2 (en) 2020-02-07 2022-12-14 ModernaTX, Inc. Sars-cov-2 mrna domain vaccines
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
EP4149484A4 (en) 2020-05-15 2024-10-02 ModernaTX, Inc. RNA FORMULATIONS FOR HIGH VOLUME DELIVERY
WO2021237084A1 (en) 2020-05-21 2021-11-25 Modernatx, Inc. Methylene blue stabilized mrna compositions
EP4162055A4 (en) 2020-06-05 2024-07-03 ModernaTX, Inc. Bacterial strains for dna production
MA71659A (fr) 2020-08-06 2025-05-30 Modernatx, Inc. Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
US20220110884A1 (en) 2020-10-12 2022-04-14 Translate Bio, Inc. Process of preparing mrna-loaded lipid nanoparticles
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
JP2024503699A (ja) 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド バリアント株ベースのコロナウイルスワクチン
US20240100145A1 (en) 2021-03-05 2024-03-28 Moderna TX, Inc. Vlp enteroviral vaccines
US20240299531A1 (en) 2021-03-15 2024-09-12 Moderna TX, Inc Therapeutic use of sars-cov-2 mrna domain vaccines
EP4313072A1 (en) 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4314000A1 (en) 2021-03-31 2024-02-07 ModernaTX, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
WO2022212711A2 (en) 2021-04-01 2022-10-06 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
WO2022212191A1 (en) 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
EP4322993A1 (en) 2021-04-13 2024-02-21 ModernaTX, Inc. Respiratory virus combination vaccines
EP4322997A4 (en) 2021-04-13 2025-02-26 ModernaTX, Inc. EPSTEIN-BARR VIRUS mRNA VACCINES
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
TW202308658A (zh) 2021-04-23 2023-03-01 美商現代公司 異喹啉穩定之脂質奈米粒子調配物
WO2022232585A1 (en) 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
BR112023022928A2 (pt) 2021-05-03 2024-01-23 Pfizer Composição imunogênica contra gripe
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
EP4355761A1 (en) 2021-06-14 2024-04-24 ModernaTX, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
EP4355891A4 (en) 2021-06-14 2025-09-24 Modernatx Inc VACCINES AGAINST CORONAVIRUS GLYCOSYLATION VARIANTS
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
US20240382581A1 (en) 2021-07-09 2024-11-21 Modernatx, Inc. Pan-human coronavirus vaccines
WO2023283645A1 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus domain vaccines
WO2023283642A2 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
EP4381059A1 (en) 2021-08-02 2024-06-12 ModernaTX, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
WO2023019181A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Sars-cov-2 lipid nanoparticle vaccine formulations
US20250281418A1 (en) 2021-08-11 2025-09-11 Modernatx, Inc. Lipid nanoparticle formulations and methods of synthesis thereof
EP4384613A1 (en) 2021-08-13 2024-06-19 ModernaTX, Inc. Multicolumn chromatography mrna purification
WO2023056401A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
JP2024540917A (ja) 2021-10-18 2024-11-06 モデルナティエックス インコーポレイテッド 組み換えタンパク質生産のためのカスタム株
WO2023069895A1 (en) 2021-10-18 2023-04-27 Modernatx, Inc. Markerless dna production
US20250231165A1 (en) 2021-10-20 2025-07-17 Modernatx, Inc. Drug product surrogate solutions
WO2023076358A1 (en) 2021-10-26 2023-05-04 Exopolymer, Inc. Heat stable and/or heat activated biopolymers
EP4426855A1 (en) 2021-11-05 2024-09-11 ModernaTX, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US20250360194A1 (en) 2021-12-08 2025-11-27 Modernatx, Inc. Herpes simplex virus mrna vaccines
US20250067729A1 (en) 2021-12-15 2025-02-27 ModrnaTX, Inc. Determination of encapsulation efficiency of lipid nanoparticles
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
US20250136970A1 (en) 2022-02-03 2025-05-01 Modernatx, Inc. Continuous precipitation for mrna purification
WO2023154818A1 (en) 2022-02-09 2023-08-17 Modernatx, Inc. Mucosal administration methods and formulations
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
EP4508242A1 (en) 2022-04-11 2025-02-19 ModernaTX, Inc. Detection of mrna purity in a mixture
US20250250551A1 (en) 2022-04-14 2025-08-07 Modernatx, Inc. Rna polymerase variants
US20250251391A1 (en) 2022-04-15 2025-08-07 Modernatx, Inc. Ribosomal engagement potency assay
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
US20250340586A1 (en) 2022-05-17 2025-11-06 Modernatx, Inc. Preparation of highly concentrated mrna

Also Published As

Publication number Publication date
SG10201912038TA (en) 2020-02-27
CA3177878A1 (en) 2015-10-29
EP3134131A4 (en) 2018-06-13
LT3134131T (lt) 2022-02-10
RU2021109685A (ru) 2021-04-13
SMT202200158T1 (it) 2022-05-12
US20190015501A1 (en) 2019-01-17
MA59052B1 (fr) 2025-01-31
LT3981437T (lt) 2025-01-10
US12329812B2 (en) 2025-06-17
US20240390480A1 (en) 2024-11-28
AU2015249553B2 (en) 2021-03-04
US20240398927A9 (en) 2024-12-05
US20240408191A1 (en) 2024-12-12
JP6881813B2 (ja) 2021-06-02
HUE069770T2 (hu) 2025-04-28
RU2016145597A3 (pl) 2018-12-07
US20190008948A1 (en) 2019-01-10
SMT202500052T1 (it) 2025-03-12
PL3981437T3 (pl) 2025-02-24
AU2024266879A1 (en) 2024-12-12
DK3134131T3 (en) 2022-02-07
RU2746406C2 (ru) 2021-04-13
PT4023249T (pt) 2025-01-14
US10022435B2 (en) 2018-07-17
US12274743B2 (en) 2025-04-15
SI3134131T1 (sl) 2022-04-29
ES2909180T3 (es) 2022-05-05
BR112016024644A2 (pt) 2017-10-10
US20160317647A1 (en) 2016-11-03
US10709779B2 (en) 2020-07-14
SI4023249T1 (sl) 2025-03-31
EP3134131B1 (en) 2021-12-22
US20160331828A1 (en) 2016-11-17
EP3981437B1 (en) 2024-10-09
JP7504464B2 (ja) 2024-06-24
AU2015249553A1 (en) 2016-11-10
ES3009962T3 (en) 2025-03-31
HRP20220070T1 (hr) 2022-04-01
SI3981437T1 (sl) 2025-04-30
US20190000959A1 (en) 2019-01-03
HRP20241733T1 (hr) 2025-02-28
EP4501318A3 (en) 2025-05-14
US20240398931A1 (en) 2024-12-05
SMT202500053T1 (it) 2025-03-12
EP4023249B1 (en) 2024-10-09
JP2021091689A (ja) 2021-06-17
US20210220467A1 (en) 2021-07-22
JP2017513956A (ja) 2017-06-01
EP3134131A1 (en) 2017-03-01
FI3981437T3 (fi) 2025-01-10
HUE057800T2 (hu) 2022-06-28
US20220193223A1 (en) 2022-06-23
SG11201608798YA (en) 2016-11-29
CN106659803A (zh) 2017-05-10
EP4023249A1 (en) 2022-07-06
FI4023249T3 (fi) 2025-01-09
PT3134131T (pt) 2022-03-24
WO2015164674A1 (en) 2015-10-29
CA2946751A1 (en) 2015-10-29
EP3981437A1 (en) 2022-04-13
LT4023249T (lt) 2025-01-10
RS66380B1 (sr) 2025-02-28
CY1125084T1 (el) 2024-02-16
RS63050B1 (sr) 2022-04-29
RU2016145597A (ru) 2018-05-24
US9872900B2 (en) 2018-01-23
HRP20241732T1 (hr) 2025-02-28
AU2021203492A1 (en) 2021-06-24
DK3981437T3 (da) 2025-01-13
ES3003986T3 (en) 2025-03-11
DK4023249T3 (da) 2025-01-13
HUE069802T2 (hu) 2025-04-28
PT3981437T (pt) 2025-01-15
JP2024071384A (ja) 2024-05-24
PL3134131T3 (pl) 2022-04-11
RS66388B1 (sr) 2025-02-28
MA58292B1 (fr) 2025-01-31
EP4501318A2 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
DK3134131T3 (en) Nucleic acid vaccines
SMT201900169T1 (it) Acido nucleico antisenso
SG11201610168YA (en) Nucleic acid synthesis techniques
GB201410971D0 (en) Vaccine
GB201507119D0 (en) Nucleic Acid Construct
GB201507115D0 (en) Nucleic Acid Construct
GB201507111D0 (en) Nucleic acid construct
GB201507104D0 (en) Nucleic acid construct
GB201507108D0 (en) Nucleic acid construct
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
GB201405226D0 (en) Nucleic acid preparation method
GB201408841D0 (en) Nucleic acid processing
GB201415674D0 (en) Nucleic acid analysis
PL3188755T3 (pl) Szczepionka
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
HK1235003A1 (zh) 核酸疫苗
GB201518917D0 (en) Vaccination
GB201503266D0 (en) Vaccination
GB201402630D0 (en) Nucleic acid amplification